Pharmafile Logo

Idis Managed Access

- PMLiVE

The importance of real-world data to the pharma industry

It is a crucial time to for pharma and other stakeholders to demonstrate medicines' value

- PMLiVE

The blame game

In the 'healthcare spending crisis' it’s important to look beyond sensationalist headlines

- PMLiVE

Overcoming quantitative pricing limitations

Choosing an accurate price for a product without a therapeutic equivalent can feel like a lead in the dark

- PMLiVE

Patient survey finds pharma falls short on drug pricing

The industry is coming under increasing attack from all sides as price tags rise

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

US lawmakers pass new bill to speed up drug reviews

FDA will also need to take the views of patients into greater consideration under new plans

- PMLiVE

George Freeman re-appointed as UK life science minister

Industry welcomes his continuation in this pharma-focused role

- PMLiVE

Is a UK market access shake-up on the cards?

Former coalition government health minister Paul Burstow tells PMLiVE that NICE, QALY and broader issues of market access in England are all being put under review

ABPI London offices

Pharma must engage on the affordability question, says ABPI

UK pharma trade body says the industry must be willing to discuss drug pricing

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links